APR September/October 2020 - 114

»

ROUNDTABLE

»

Drug Delivery
Roundtable

Over the past year can you tell us
about one critical issue that has most
affected new drug delivery efforts?
Satish Shetty, Director of Product Development, Cambrex: In 2020,
the most critical issue has become the COVID-19 pandemic situation.
This has affected new drug delivery efforts in two ways:

Satish Shetty
Director of Product Development
Cambrex

1.

and globalization issues
2.

Susan Banbury
Head of Zydis Formulation
Catalent

a disruption in the supply chain impacting availability of
active pharmaceutical ingredients (APIs) due to sourcing
a shift in focus from existing or new development programs
to COVID-centric programs (vaccines and treatments)

The global API market is estimated to reach USD 245.2 billion by 2024
from USD 182.2 billion in 2019. Chinese and Indian manufacturers
account for more than 50% of all APIs used worldwide, which could

Tom Tice
Senior Director, Global Technical Marketing for Parenteral Drug Delivery
Evonik

grow as the market grows. During the spring of 2020, as COVID
lockdowns first started happening, we saw fractures in the supply
chain based on shipping and trade challenges. This glimpse into the
"what if" of losing access to certain APIs made the large reliance on Asia

Dr. Jessica Mueller-Albers
Strategic Marketing Director, Oral Drug Delivery
Evonik
Stephen Carino
Manager, Early Development
Catalent

a deep concern because the adequate supply of APIs is the backbone
for developing drug delivery systems.
Indeed, the pandemic has served as a wake-up call to counter the
dominance of India and China in the world supply of APIs. Western
governments need to take initiative and encourage domestic
production of active pharmaceutical ingredients.
Susan Banbury, Head of Zydis Formulation, Catalent: The biggest
drug delivery challenge encountered over the last year is that of
overcoming bioavailability issues. This may be due to very low
solubility of the active pharmaceutical ingredient (API) and consequent
dissolution rate limited absorption. In such cases, formulation
and processing efforts focus on improving the API's solubility, for
example through excipient choice or pH modification, or increasing
its surface area via micronization. These techniques can present their

114 |

APR_SeptOct2020.indd 114

| September/October 2020

10/2/20 11:46 AM



APR September/October 2020

Table of Contents for the Digital Edition of APR September/October 2020

Table of Contents
APR September/October 2020 - Cover1
APR September/October 2020 - Cover2
APR September/October 2020 - 1
APR September/October 2020 - 2
APR September/October 2020 - Table of Contents
APR September/October 2020 - 4
APR September/October 2020 - 5
APR September/October 2020 - 6
APR September/October 2020 - 7
APR September/October 2020 - 8
APR September/October 2020 - 9
APR September/October 2020 - 10
APR September/October 2020 - 11
APR September/October 2020 - 12
APR September/October 2020 - 13
APR September/October 2020 - 14
APR September/October 2020 - 15
APR September/October 2020 - 16
APR September/October 2020 - 17
APR September/October 2020 - 18
APR September/October 2020 - 19
APR September/October 2020 - 20
APR September/October 2020 - 21
APR September/October 2020 - 22
APR September/October 2020 - 23
APR September/October 2020 - 24
APR September/October 2020 - 25
APR September/October 2020 - 26
APR September/October 2020 - 27
APR September/October 2020 - 28
APR September/October 2020 - 29
APR September/October 2020 - 30
APR September/October 2020 - 31
APR September/October 2020 - 32
APR September/October 2020 - 33
APR September/October 2020 - 34
APR September/October 2020 - 35
APR September/October 2020 - 36
APR September/October 2020 - 37
APR September/October 2020 - 38
APR September/October 2020 - 39
APR September/October 2020 - 40
APR September/October 2020 - 41
APR September/October 2020 - 42
APR September/October 2020 - 43
APR September/October 2020 - 44
APR September/October 2020 - 45
APR September/October 2020 - 46
APR September/October 2020 - 47
APR September/October 2020 - 48
APR September/October 2020 - 49
APR September/October 2020 - 50
APR September/October 2020 - 51
APR September/October 2020 - 52
APR September/October 2020 - 53
APR September/October 2020 - 54
APR September/October 2020 - 55
APR September/October 2020 - 56
APR September/October 2020 - 57
APR September/October 2020 - 58
APR September/October 2020 - 59
APR September/October 2020 - 60
APR September/October 2020 - 61
APR September/October 2020 - 62
APR September/October 2020 - 63
APR September/October 2020 - 64
APR September/October 2020 - 65
APR September/October 2020 - 66
APR September/October 2020 - 67
APR September/October 2020 - 68
APR September/October 2020 - 69
APR September/October 2020 - 70
APR September/October 2020 - 71
APR September/October 2020 - 72
APR September/October 2020 - 73
APR September/October 2020 - 74
APR September/October 2020 - 75
APR September/October 2020 - 76
APR September/October 2020 - 77
APR September/October 2020 - 78
APR September/October 2020 - 79
APR September/October 2020 - 80
APR September/October 2020 - 81
APR September/October 2020 - 82
APR September/October 2020 - 83
APR September/October 2020 - 84
APR September/October 2020 - 85
APR September/October 2020 - 86
APR September/October 2020 - 87
APR September/October 2020 - 88
APR September/October 2020 - 89
APR September/October 2020 - 90
APR September/October 2020 - 91
APR September/October 2020 - 92
APR September/October 2020 - 93
APR September/October 2020 - 94
APR September/October 2020 - 95
APR September/October 2020 - 96
APR September/October 2020 - 97
APR September/October 2020 - 98
APR September/October 2020 - 99
APR September/October 2020 - 100
APR September/October 2020 - 101
APR September/October 2020 - 102
APR September/October 2020 - 103
APR September/October 2020 - 104
APR September/October 2020 - 105
APR September/October 2020 - 106
APR September/October 2020 - 107
APR September/October 2020 - 108
APR September/October 2020 - 109
APR September/October 2020 - 110
APR September/October 2020 - 111
APR September/October 2020 - 112
APR September/October 2020 - 113
APR September/October 2020 - 114
APR September/October 2020 - 115
APR September/October 2020 - 116
APR September/October 2020 - 117
APR September/October 2020 - 118
APR September/October 2020 - 119
APR September/October 2020 - 120
APR September/October 2020 - 121
APR September/October 2020 - 122
APR September/October 2020 - 123
APR September/October 2020 - 124
APR September/October 2020 - 125
APR September/October 2020 - 126
APR September/October 2020 - 127
APR September/October 2020 - 128
APR September/October 2020 - 129
APR September/October 2020 - 130
APR September/October 2020 - 131
APR September/October 2020 - 132
APR September/October 2020 - 133
APR September/October 2020 - 134
APR September/October 2020 - 135
APR September/October 2020 - 136
APR September/October 2020 - 137
APR September/October 2020 - 138
APR September/October 2020 - 139
APR September/October 2020 - 140
APR September/October 2020 - 141
APR September/October 2020 - 142
APR September/October 2020 - 143
APR September/October 2020 - 144
APR September/October 2020 - 145
APR September/October 2020 - 146
APR September/October 2020 - 147
APR September/October 2020 - 148
APR September/October 2020 - 149
APR September/October 2020 - 150
APR September/October 2020 - 151
APR September/October 2020 - 152
APR September/October 2020 - 153
APR September/October 2020 - 154
APR September/October 2020 - 155
APR September/October 2020 - 156
APR September/October 2020 - 157
APR September/October 2020 - 158
APR September/October 2020 - 159
APR September/October 2020 - 160
APR September/October 2020 - 161
APR September/October 2020 - 162
APR September/October 2020 - 163
APR September/October 2020 - 164
APR September/October 2020 - 165
APR September/October 2020 - 166
APR September/October 2020 - 167
APR September/October 2020 - 168
APR September/October 2020 - Cover3
APR September/October 2020 - Cover4
https://www.nxtbook.com/comparenetworks/AmericanPharmaceuticalRevew/apr-innovations-at-interphex-guide-april-2022
https://www.nxtbook.com/comparenetworks/AmericanPharmaceuticalRevew/APRNovDec2020
https://www.nxtbook.com/comparenetworks/AmericanPharmaceuticalRevew/APRSeptOct2020
https://www.nxtbookmedia.com